Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months...
Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business developmentMARLBOROUGH, Mass....
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA)...
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2...
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression...
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing...
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone...
Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiariesMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April...
WASHINGTON, April 10, 2024 (GLOBE NEWSWIRE) -- The American Council of the Blind (ACB), the American Foundation for the Blind...
Enrollment to continue to the end of April to accommodate strong patient and site interestNAARDEN, the Netherlands and MIAMI, April...
The ‘My Mental Health Journey’ registry is now enrolling U.S.-based adults experiencing symptoms of depression. The Otsuka-sponsored registry study is...
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine candidateKey takeaways:Participants in...
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced the release of its annual...
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Preliminary SI Joint Fusion Results Based on Independent Radiologist Review Indicate Robust Fusion at 12-Months Post-ProcedureInitial Patient Results Demonstrate Marked...
Bicameral legislation seeks to codify annual examinations and assessments for assistive technologies, including Personal Exoskeletons, for Veterans with Spinal Cord...
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a...